Related by context. All words. (Click for frequent words.) 78 A1C levels 77 hemoglobin A1c levels 76 HbA1c levels 75 HbA 1c 75 HbA1C levels 74 Hb A1C 74 HbA1C 73 glycated hemoglobin levels 73 HbA 1c levels 73 baseline HbA1c 72 PASI scores 72 hemoglobin A1c HbA1c 70 serum urate 70 hemoglobin A1C 69 glycosylated hemoglobin HbA1c 69 albumin excretion 69 nonfasting triglyceride levels 69 sUA 69 serum uric acid 69 glycated hemoglobin 69 HbA1c 69 serum phosphate 69 serum urate levels 68 plasma glucose levels 68 CCyR 68 postoperative mortality 68 hemoglobin A1c 68 serum phosphorus 68 serum calcium levels 68 HbA 1C 68 pCR 68 troponin T 67 PSADT 67 platelet reactivity 67 RBP4 levels 67 glycated hemoglobin HbA1c 67 #mg/dL [001] 67 complete cytogenetic response 67 sUA levels 67 PSA nadir 67 asymptomatic carotid stenosis 67 neutrophil counts 67 Fasting glucose 67 HBeAg seroconversion 67 serum testosterone 67 adenoma recurrence 67 serum phosphate levels 67 HOMA IR 67 #mmHg [001] 67 recurrent VTE 67 serum clusterin levels 66 #.#mmol L [002] 66 hemoglobin concentrations 66 lumbar spine BMD 66 #.#/#.# mmHg [001] 66 mmol l 66 baseline A1C 66 serum creatinine levels 66 hydroxyvitamin D levels 66 CLA supplementation 66 glycosylated hemoglobin levels 66 iPTH 66 hsCRP levels 66 NPH insulin 66 serum calcium 66 mL/min/#.# m 2 66 ejection fractions 65 fasting plasma glucose 65 urate levels 65 fasting glucose levels 65 serum potassium 65 thyrotropin levels 65 intima media thickness 65 nocturnal hypoglycaemia 65 albumin excretion rate 65 CVD mortality 65 lipid lowering medications 65 sustained virological response 65 antihypertensive medications 65 A1c 65 microvascular complications 65 MS relapses 65 EDSS score 65 statistical significance p 65 glomerular filtration rate 65 carotid IMT 65 hypoglycemic episodes 65 cTnT levels 65 Crohn Disease Activity 65 thiazide diuretics 65 Hb A1c 65 #mmHg [002] 65 glycemia 65 #mg dose [002] 65 OGTT 65 polyp recurrence 65 #/#mmHg 65 magnesium intake 65 alanine aminotransferase ALT 64 CDAI score 64 aminotransferases 64 definite stent thrombosis 64 sustained virologic response 64 binary restenosis 64 serum IGF 64 advanced adenomas 64 dose colchicine 64 annualized relapse 64 serum aminotransferase levels 64 urine albumin 64 poor metabolizers 64 plasma HCV RNA 64 glomerular filtration 64 adiponectin levels 64 angiographic restenosis 64 virologic failure 64 plasma triglycerides 64 BENICAR HCT 64 corticosteroid dose 64 glycosylated hemoglobin 64 IOP lowering 64 baseline LDH 64 serum sodium 63 nondiabetic patients 63 blood Phe levels 63 platelet inhibition 63 CHD mortality 63 triacylglycerol concentrations 63 triglyceride concentrations 63 lipid parameters 63 serum LDL cholesterol 63 NNT = 63 elevated ALT 63 serum concentrations 63 dose statin therapy 63 serum homocysteine 63 fasting insulin 63 XIENCE V PROMUS Stent 63 fasting triglyceride levels 63 morphometric vertebral fractures 63 atorvastatin #mg 63 advanced adenoma 63 serum phosphorus levels 63 reinfarction 63 SHBG levels 63 antihypertensive therapy 63 blood glucose concentrations 63 blood glucose levels 63 antibody titer 63 Triglyceride levels 63 serum testosterone levels 63 nocturnal hypoglycemia 63 infarct size 63 mm Hg diastolic 63 hip BMD 63 elevated LDL cholesterol 63 biochemical recurrence 63 systemic embolism 63 CrCl 63 LDL cholesterol levels 63 recurrent venous thromboembolism 63 NATRECOR R 63 leukocyte count 63 microalbuminuria 63 ARB telmisartan 63 HBV DNA levels 63 transaminase levels 63 colorectal adenoma 63 μg dL 63 fasting plasma glucose FPG 63 serum HBV DNA 63 serum glucose 63 lowering blood glucose 63 mEq L 63 EDSS scores 63 undetectable viral load 63 Hb levels 63 virological response 63 homocysteine concentrations 63 serum triglyceride levels 63 intact parathyroid hormone 63 fructose diet 63 fasting blood glucose 63 undetectable viral 63 statin monotherapy 63 A1Cs 63 gastric pH 62 per deciliter mg 62 arterial thromboembolic events 62 attain statistical significance 62 bezafibrate 62 BENICAR 62 vertebral fracture 62 mmol liter 62 nonvertebral fracture 62 eosinophil count 62 peak VO2 62 #.#mmol l [002] 62 hypoglycemic events 62 prednisone prednisolone 62 #.#ng/ml 62 MMSE scores 62 #mg/dL [002] 62 MADRS score 62 MMSE score 62 ACR# response 62 intensive statin therapy 62 % Confidence Interval 62 mm Hg systolic 62 CR nPR 62 biochemical relapse 62 severe exacerbations 62 nondiabetics 62 virological suppression 62 oral antidiabetic medication 62 metabolic parameters 62 virological failure 62 gout flares 62 virologic response 62 octreotide LAR 62 subclinical atherosclerosis 62 NIHSS score 62 uric acid levels 62 achieved ACR# 62 triglyceride concentration 62 creatinine clearance 62 tapentadol ER 62 nonvertebral fractures 62 dosing frequency 62 elevated IOP 62 A1C 62 fat vegan diet 62 oral antidiabetes 62 serum phosphorous 62 #OHD levels 62 lipid lowering therapy 62 serum folate 62 serum lipid levels 62 periprocedural 62 timepoints 62 postprandial glucose 61 elevated creatinine 61 mean baseline HbA1c 61 PRADAXA #mg 61 serum PTH 61 prospectively defined 61 eGFR 61 exhaled NO 61 lowering systolic blood 61 certolizumab 61 QTcF 61 incontinence episodes 61 serum potassium levels 61 serum HCV RNA 61 T2DM 61 lipid lowering drugs 61 oxycodone CR 61 ng dL 61 perioperative mortality 61 salivary flow 61 β blockers 61 lowest tertile 61 serum uric acid sUA 61 isoflavone intake 61 μmol L 61 hypertensives 61 serum estradiol 61 noncardiovascular mortality 61 MoxDuo TM IR 61 liver histology 61 folate intake 61 nmol L 61 normal ULN 61 FeNO 61 neurodevelopmental impairment 61 insulin detemir 61 serum PSA 61 lispro 61 atherogenic dyslipidemia 61 elevated triglyceride levels 61 QALE 61 Kaplan Meier analysis 61 aspartate aminotransferase AST 61 evaluable subjects 61 diastolic blood pressures 61 serum vitamin D 61 mg dl 61 mg simvastatin 61 glycemic variability 61 glycaemia 61 paricalcitol 61 subclinical hypothyroidism 61 foveal thickness 61 CK MB 61 oocytes retrieved 61 Index CDAI score 61 Score DAS# 61 teriflunomide 61 improves glycemic 61 pulmonary capillary wedge 61 systolic hypertension 61 log# copies mL 61 prolactin levels 61 serum triglycerides 61 ALT elevation 61 μg L 61 systolic BP 61 nicardipine 61 Homocysteine levels 61 highest tertile 61 creatinine levels 61 periprocedural MI 61 biphasic insulin aspart 61 mean serum phosphorus 61 mg dL 61 virologic suppression 61 postprandial blood glucose 61 umol L 61 lipid lowering agents 61 acarbose 61 rimonabant #mg 61 abacavir lamivudine 61 folic acid intake 61 ACCORD Lipid 61 glargine 61 MetS 61 endometrial thickness 61 atheroma volume 61 residual platelet reactivity 61 postoperative complication 61 fasting glucose 61 seroprotection 61 nonfatal MI 61 thyrotropin 61 steroid dexamethasone 61 hypertensive patients 61 conventional antipsychotics 61 urinary albumin 61 plasma homocysteine 61 coronary stenosis 61 elevated CRP 61 antihypertensive medication 61 hsCRP 61 prospectively stratified 61 aminotransferase ALT 61 tHcy 61 dose clopidogrel 61 tertiles 61 Fasting plasma glucose 60 symptomatic intracranial hemorrhage 60 Scale EDSS score 60 lymphocyte count 60 Primary endpoints 60 systolic dysfunction 60 mmHg diastolic 60 testosterone supplementation 60 hypogonadal men 60 glulisine 60 alanine aminotransferase 60 serum cholesterol 60 Insulin sensitivity 60 tertile 60 peak plasma concentrations 60 Apgar scores 60 nonfasting triglycerides 60 DAS# [002] 60 mIU L 60 NIHSS 60 estimated GFR 60 DAS# scores 60 serum cortisol 60 symptomatic VTE 60 aminotransferase levels 60 dose Iluvien 60 SCr 60 oral antidiabetic drugs 60 death reinfarction 60 R0 resection 60 g dl 60 tirofiban 60 severe hypoglycaemia 60 endoscopic remission 60 dose atorvastatin 60 QIDS SR 60 detectable HCV RNA 60 International Normalized Ratio 60 BMI percentiles 60 secondary efficacy endpoint 60 macrovascular events 60 AST ALT 60 fasting triglycerides 60 serum ALT 60 LDL lowering 60 mIU ml 60 creatinine ratio 60 fluvastatin 60 nmol l 60 fluticasone salmeterol 60 % CI #.#-#.# [008] 60 complete cytogenetic 60 carotid stenosis 60 KRAS mutations occur 60 postoperative AF 60 FDA defined valvulopathy 60 CRp 60 macroalbuminuria 60 X ULN 60 STRIDE PD 60 ADCS CGIC 60 SUVmax 60 sulphonylureas 60 inhospital 60 urinary N telopeptide 60 Ejection Fraction 60 EBRT 60 retinal thickness 60 dose dabigatran 60 LV dysfunction 60 LDL C 60 g dL 60 AZOR 60 CK # plasma concentrations 60 beta blocker therapy 60 MICARDIS ® 60 metformin sulphonylurea 60 triglyceride levels 60 dose pravastatin 60 apolipoprotein B 60 ARCOXIA 60 confirmed CCyR 60 CPAP adherence 60 achieved statistical significance 60 postintervention 60 tumor recurrence 60 #mg dose [003] 60 glycemic diet 60 cardiovascular morbidity 60 estimated glomerular filtration 60 preoperative chemotherapy 60 Breslow thickness 60 HER2 expression 60 #mg/day [001] 60 hematologic toxicity 60 HIV HCV coinfected 60 APTIVUS r 60 colorectal polyp 60 mg BID dose 60 x ULN 60 dose cohort 60 density lipoprotein cholesterol 60 Viral load 60 dapagliflozin plus 60 atypical antipsychotic medications 60 HAQ DI 60 postprandial glycemia 60 arterial thickening 60 plasma uric acid 60 relapsed MM 60 OADs 60 moderate renal impairment 60 recurrent atrial fibrillation 60 insulin glargine 60 perioperative morbidity 60 mucosal healing 60 TNF antagonist 60 plasma glucose concentration 60 ruboxistaurin 60 rebleeding 60 glimepiride 59 thigh circumference 59 repeat revascularization 59 isoprostane 59 BLLs 59 rosuvastatin #mg 59 trans fat intake 59 revascularizations 59 mesalamine granules 59 ULORIC 59 prescribed statins 59 dietary calcium intake 59 μg dose 59 urate lowering therapy 59 NovoLog ® Mix 59 Recurrence Score 59 Lupuzor ™ 59 dosage regimens 59 arterial stiffness 59 serum TSH 59 alteplase 59 pg mL 59 cilostazol 59 cardiovascular hospitalizations 59 -#.# mg dL [002] 59 mU L 59 transferrin saturation 59 LDL Cholesterol 59 antidiabetic medication 59 LVEF 59 tipranavir r 59 dyslipidaemia 59 hemoglobin concentration 59 urinary oxalate 59 treat NNT 59 LDL cholesterol lowering 59 thyroid hormone levels 59 apnea hypopnea index 59 mycophenolate mofetil 59 Hemoglobin A1c 59 Contrave# 59 hemoglobin A1C HbA1C 59 intraocular pressure IOP 59 protein excretion 59 plasma leptin 59 cyclic HMB 59 p = #.# [003] 59 Calcium intake 59 XIENCE V demonstrated 59 KIF6 carriers 59 haemorrhagic stroke 59 #.#mg/dL 59 mealtime insulin 59 mmHg systolic 59 baseline serum creatinine 59 antioxidant supplementation 59 detemir 59 chlorthalidone 59 Fibrates 59 coronary artery calcification 59 DAS# CRP 59 inflammatory biomarkers 59 androgen deprivation 59 ipsilateral stroke 59 KDOQI 59 Secondary efficacy endpoints 59 CDI recurrence 59 postprocedure 59 neurologic progression 59 nonadherence 59 procalcitonin 59 venlafaxine XR 59 COPD exacerbation 59 Reynolds Risk Score 59 adrenal function 59 Ishak fibrosis score 59 urinary albumin excretion 59 Complication rates 59 bilirubin levels 59 noninferiority 59 PV module efficiencies 59 remission CR 59 Cmax 59 calculated creatinine clearance 59 statistically nonsignificant 59 comorbid conditions 59 VADT 59 cerebrovascular events 59 vildagliptin 59 metformin sulfonylurea 59 aldosterone antagonists 59 N telopeptide 59 CIMZIA ™ 59 cardio respiratory fitness 59 DAS# remission 59 PSA velocity 59 oral diclofenac 59 transaminases 59 impaired fasting glucose 59 plasma folate 59 cardiovascular mortality 59 serum magnesium 59 PCWP 59 cecal intubation 59 % CI #.#-#.# [003] 59 cinacalcet 59 ml kg 59 8 OHdG 59 #ng/ml 59 alemtuzumab treated 59 T1DM 59 anemia hemoglobin 59 nmol L. 59 mg/m2 dose 59 mammographic density 59 inhaled corticosteroids ICS 59 albuminuria 59 QTc prolongation 59 BMI z 59 nocturnal awakenings 59 symptomatic intracerebral hemorrhage 59 lipid elevations 59 K DOQI 59 MCyR 59 Subgroup analyzes 59 Febrile neutropenia 59 plasma glucose 59 IR Cysteamine 59 colorectal neoplasia 59 dosing cohort 59 sputum eosinophils 59 #mg doses [002] 59 Severe hypoglycemia 59 thiazides 59 hyperphenylalaninemia HPA due 59 NYHA functional class 59 urinary cortisol 59 cytogenetic response 59 PRADAXA 59 oral FTY# 59 variceal bleeding 59 recurrent ischemia 59 nondepressed 59 prehypertensive 59 severe asthma exacerbations 59 endometrial hyperplasia 59 μg liter 59 paroxysmal AF 59 weekly CSBMs 59 ABC/3TC 59 tibolone 59 multivariable analysis 59 elevated uric acid 59 fosamprenavir 59 warfarin dose 59 macrovascular 59 glucose lowering 59 pg ml 59 colorectal cancer incidence 59 mmol L. 59 mmHg 59 lipid lowering medication 59 CHD CVD 59 serum parathyroid hormone 59 % CI #.#-#.# [004] 59 corrected QT interval 59 hepatic insulin sensitivity 59 adjunctive placebo 59 salmeterol fluticasone 59 abdominal adiposity 59 TEAEs 59 bupropion SR 59 specific antigen PSA 58 Baseline characteristics 58 acromegalic patients 58 Zevalin consolidation 58 nmol liter 58 XEPLION R 58 exhaled nitric oxide 58 EDARBI 58 cTnT 58 IFN beta 58 Pioglitazone 58 Fasting blood glucose 58 arterial oxygen saturation 58 atherothrombotic events 58 d dimer 58 diastolic BP 58 clinically meaningful improvement 58 antiarrhythmic drug 58 Diastolic pressure 58 lanthanum carbonate 58 prespecified 58 benazepril 58 doxorubicin docetaxel 58 clomipramine 58 clodronate 58 cardiac autonomic 58 milligrams deciliter 58 efficacy endpoint 58 growth hormone secretion 58 spontaneous preterm delivery 58 FOLFOX4 58 advanced neoplasia 58 desvenlafaxine succinate 58 confidence intervals CIs 58 subcutaneous insulin 58 #.#mmol L [001] 58 preintervention 58 IBS symptoms 58 CR CRu 58 autoantibody levels 58 statistically significant p = 58 locoregional recurrence 58 Intraocular pressure 58 ivabradine 58 femoral neck BMD 58 rosuvastatin 58 hs CRP 58 low dose Iluvien 58 serum retinol 58 mg dose 58 PON1 enzyme 58 severe hypoglycemia 58 NNRTI resistance 58 abnormal lipid 58 mm ³ 58 salmeterol fluticasone propionate 58 GI toxicity 58 transaminase elevations 58 pyridostigmine 58 Tekamlo 58 ANCHOR trial 58 #mg/dl 58 flutamide 58 Avandia Actos 58 oral hypoglycemic agent 58 plasma homocysteine levels 58 ALT flares 58 Non inferiority 58 nephrotoxicity 58 myocardial reperfusion 58 receiving Vectibix monotherapy 58 #mg/day [002] 58 leucopenia 58 radiographic progression 58 intraocular pressure 58 Cortisol levels 58 #.#mmHg 58 subclinical hyperthyroidism 58 PREZISTA r arm 58 Complications Trial 58 comparator arm 58 lipoprotein levels 58 aripiprazole 58 secondary efficacy endpoints 58 antidiabetic drugs 58 lipid profiles 58 depressive symptomatology 58 mg kg dose 58 sulphonylurea 58 diastolic pressure 58 telomere lengths 58 pramlintide metreleptin combination 58 sitagliptin 58 homocysteine levels 58 dose cytarabine 58 obese adolescents 58 UPDRS scores 58 hemorrhagic complications 58 atherogenic lipids 58 antihypertensive drugs 58 interquartile range 58 vaginal progesterone gel 58 DLQI 58 cardioembolic stroke 58 elevated triglycerides 58 overt nephropathy 58 receiving golimumab 58 conditional logistic regression 58 Radical prostatectomy 58 lipid levels 58 HBeAg 58 baseline PASI 58 HAART regimens 58 B7 H3 58 liver enzymes ALT 58 REYATAZ r arm 58 severe renal impairment 58 androgen depletion 58 undergoing bariatric surgery 58 lowering homocysteine 58 cranial irradiation 58 revascularization procedures 58 statin therapy 58 ACR# responses 58 antiandrogen 58 Operative mortality 58 aldosterone antagonist 58 log# reduction 58 histologic subtype 58 symptomatic carotid stenosis 58 blood Phe 58 osteopenic 58 oral antidiabetics 58 mL/min/#.# m2 58 VTEs 58 HDL C 58 Insulin PH# 58 eplerenone 58 carb dieters 58 Ramipril 58 coronary revascularization 58 Stent thrombosis 58 nonfatal myocardial infarction 58 echocardiographic parameters 58 fraction LVEF 58 elevated hsCRP 58 serum sodium levels 58 preoperative PSA 58 tipranavir 58 thrombotic events 58 metformin monotherapy 58 HSCT 58 erection hardness 58 ALND 58 aPTT 58 Kaplan Meier estimates 58 HBeAg negative patients 58 nonsignificant 58 hours postdose 58 angiotensin II receptor blockers 58 dose ionizing radiation 58 COPD exacerbations 58 tranylcypromine 58 angiotensin receptor blockers ARBs 58 tolterodine ER 58 adenotonsillectomy 58 macrovascular disease 58 deferasirox 58 systolic pressure 58 Index CDAI 58 calcium intakes 58 experienced virologic failure 58 severe hypoglycemic 58 ibandronate 58 titrated glipizide 58 ATACAND 58 contrast induced nephropathy 58 paroxetine Paxil 58 rosuvastatin Crestor 58 oral allopurinol 58 IELT 58 maximal doses 58 SIMPADICO 58 Interferon beta 1b 58 androgen suppression 58 #OHD 58 avosentan 58 bioavailable testosterone 58 MACCE 58 HBV DNA 58 confidence interval #.#-#.# 58 upper gastrointestinal bleeding 58 ischemic cardiomyopathy 58 mcg mL 58 intracranial hemorrhage ICH 58 statin medications 58 irbesartan 58 ICD therapy 58 psychiatric comorbidities 58 idraparinux 58 viral suppression 58 IV bisphosphonates 58 everolimus eluting stents 58 systolic blood pressure 58 TAXUS p value 58 grade cervical intraepithelial 58 rehospitalization 58 Thal Dex 58 pharmacokinetic PK profile 58 venlafaxine Effexor 58 maximally tolerated dose 58 log# IU mL 58 lymphocyte counts 58 HBV infections 58 UPDRS motor 58 refractory ischemia 58 Fasting glucose levels 58 serum lipid 58 tumor progression TTP 58 ng ml 58 newer antipsychotics 58 primary hypercholesterolemia 58 exemestane 58 arterial stiffening 58 antigen PSA levels 58 vaginal hysterectomy 58 Y BOCS 58 unfractionated heparin 58 subtrochanteric 58 clinically meaningful reductions 58 montelukast 58 hepatitis C genotype 58 dalteparin 58 IRLS score 58 #.#/#.# mm Hg [003] 57 T2 lesions 57 systemic toxicity 57 intensive lipid lowering 57 aminotransferase elevations greater 57 serum BDNF 57 osteoporotic fracture 57 oral anticoagulation 57 extrapyramidal symptoms 57 baseline FEV1 57 adiponectin concentrations 57 serum folate concentrations 57 metoprolol tartrate 57 seroconversion 57 myocardial infarctions 57 circulating lymphocytes 57 indapamide 57 cardiometabolic risk 57 neurodevelopmental outcome 57 pioglitazone 57 pmol L 57 bolus dose 57 CI -#.# 57 elevated fasting glucose 57 deep venous thromboses 57 NSTE ACS 57 mineral density 57 urine NGAL 57 Hemoglobin A1c HbA1c 57 DASH diet 57 serum CRP 57 RSV hospitalizations 57 glycemic control 57 Chlamydia infection 57 GnRH agonists 57 ertapenem 57 insulin lispro 57 ALLHAT 57 adalimumab 57 initiating HAART 57 reduce serum phosphate 57 TWYNSTA 57 infliximab monotherapy 57 plasma urate 57 SCIg 57 reintervention 57 6MWD 57 prolactin elevation 57 response CCyR 57 dose ritonavir 57 plasma concentrations 57 oxcarbazepine 57 LDL triglycerides 57 lactate dehydrogenase LDH 57 achieved sustained virological 57 achieving PASI 57 PASI score 57 paraprotein 57 paclitaxel eluting stents 57 INVEGA ® 57 baseline FEV 57 undetectable HCV RNA 57 warfarin therapy 57 extracolonic findings 57 valsartan 57 5-FU/LV 57 solifenacin 57 divalproex sodium 57 peginterferon 57 coronary revascularization procedures 57 dietary sodium intake 57 QTc intervals 57 CLBP 57 CONCERTA ® 57 mmol L 57 angiographic outcomes 57 ACE inhibitor ramipril 57 ACR Pedi 57 HRQL 57 cobiprostone 57 elevated troponin 57 bad cholesterol LDL 57 dosage regimen 57 ancrod 57 thromboembolic events 57 microvascular disease 57 cholesterol LDL C 57 fragility fracture 57 olmesartan 57 imipenem 57 -#.# log# copies mL 57 Psoriasis Area 57 SSRI SNRI 57 cardiovascular hospitalization 57 BRCA2 mutation carriers 57 TRILIPIX 57 waist girth 57 Am J Cardiol 57 cardiac troponin T 57 oral prednisolone 57 pioglitazone Actos 57 antiangiogenic therapy 57 oral rivaroxaban 57 tamoxifen Nolvadex ® 57 dose dexamethasone 57 hematopoietic cancers 57 intravenous bisphosphonates 57 luminal diameter 57 molindone 57 CTAP# Capsules 57 intracerebral haemorrhage 57 waist circumferences 57 pravastatin therapy 57 HER2 overexpression 57 CYP#D# inhibitor 57 patients undergoing CABG 57 canakinumab 57 Flu Cy 57 uncorrected visual acuity 57 undetectable HBV DNA 57 severe periodontitis 57 Scale EDSS 57 intracranial stenosis 57 eNO 57 tolvaptan